Steven K. Burke - 31 Jan 2023 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: SVP, Chief Medical Officer
Signature: /s/ Carolyn Rucci, attorney-in-fact for Steven K. Burke
Issuer symbol: AKBA
Transactions as of: 31 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2023, 15:14:30 UTC
Previous filing: 01 Sep 2022
Next filing: 01 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Award	$0	+196,200	+47%	$0.000000	615,716	31 Jan 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKBA	Stock Option (Right to buy)	Award	$0	+294,300		$0.000000	294,300	31 Jan 2023	Common Stock	294,300	$0.6300	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F2	Includes 1,500 shares of the Issuer's common stock purchased on December 30, 2022 under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.
F3	The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.